Insulet Extends Partnership with Glooko in Europe to Optimise Diabetes Data Management
“Insulet and Glooko are dedicated to bringing innovation to diabetes
management around the world. We are delighted to work together to
provide Omnipod users across
Insulet’s partnership with Glooko is further proof of its commitment to
putting customers first, as it ensures
“Glooko has a long-standing relationship with
Glooko+diasend is currently used at approximately 7,000 provider sites by over 1.5 million users in 23 countries, and the system is offered in 15 languages.
About Insulet Corporation:
Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. With Glooko, one can easily upload data from more than 160 devices such as blood glucose meters, insulin pumps, CGMs and several fitness and activity trackers — providing timely and verified data and enabling PWDs and care teams to correlate it with diet, exercise, medication and other data. Glooko provides care teams with an easy office data upload solution and a population health app so they can support PWDs during and in-between office visits. Trusted by the world’s leaders in diabetes care, Glooko is used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com.
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 22, 2018 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
Investor Relations and Corporate Communications Contact:
Deborah R. Gordon, +1 978-600-7717
Vice President, Investor Relations and Corporate Communications
Dominic Hulton, +44 20 3941 5374
Vice President, Marketing, Europe